Inspire Medical Systems (NYSE:INSP) Announces Earnings Results

Inspire Medical Systems (NYSE:INSP) posted its earnings results on Monday. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38, FiscalAI reports. The firm had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. Inspire Medical Systems updated its FY 2026 guidance to 0.750-1.250 EPS.

Inspire Medical Systems Stock Performance

Shares of INSP stock traded down $1.93 during midday trading on Monday, reaching $54.77. 1,586,372 shares of the company were exchanged, compared to its average volume of 1,178,608. Inspire Medical Systems has a 12 month low of $48.30 and a 12 month high of $163.35. The company has a market cap of $1.58 billion, a P/E ratio of 11.00, a PEG ratio of 2.92 and a beta of 0.83. The company’s 50 day moving average price is $56.73 and its two-hundred day moving average price is $79.64.

Institutional Trading of Inspire Medical Systems

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC raised its holdings in shares of Inspire Medical Systems by 40.2% in the 4th quarter. Virtu Financial LLC now owns 5,712 shares of the company’s stock worth $527,000 after purchasing an additional 1,639 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Inspire Medical Systems by 181.7% in the 4th quarter. Invesco Ltd. now owns 261,374 shares of the company’s stock worth $24,107,000 after purchasing an additional 168,587 shares in the last quarter. Corient Private Wealth LLC bought a new stake in shares of Inspire Medical Systems in the 4th quarter worth approximately $337,000. Regal Partners Ltd raised its holdings in shares of Inspire Medical Systems by 107.7% in the 4th quarter. Regal Partners Ltd now owns 211,304 shares of the company’s stock worth $19,489,000 after purchasing an additional 109,590 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. bought a new stake in shares of Inspire Medical Systems in the 4th quarter worth approximately $61,619,000. 94.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Stifel Nicolaus reduced their target price on shares of Inspire Medical Systems from $85.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, April 10th. Zacks Research lowered shares of Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 14th. Wolfe Research downgraded shares of Inspire Medical Systems from an “outperform” rating to a “peer perform” rating in a research report on Friday, February 13th. Piper Sandler dropped their price target on shares of Inspire Medical Systems from $165.00 to $85.00 and set an “overweight” rating on the stock in a research report on Thursday, February 12th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $56.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, April 14th. Five investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Inspire Medical Systems presently has an average rating of “Hold” and an average price target of $101.41.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.